Publicaciones científicas
A 20-year Follow-up of the International Early Lung Cancer Action Program (I-ELCAP)
Claudia I Henschke # 1 , Rowena Yip # 1 , Dorith Shaham 1 , Steven Markowitz 1 , José Cervera Deval 1 , Javier J Zulueta 1 , Luis M Seijo 1 , Cheryl Aylesworth 1 , Karl Klingler 1 , Shahriyour Andaz 1 , Cynthia Chin 1 , James P Smith 1 , Emanuela Taioli 1 , Nasser Altorki 1 , Raja M Flores 1 , David F Yankelevitz 1 ; International Early Lung Cancer Action Program Investigators 1
Background
The low-dose CT (≤3 mGy) screening report of 1000 Early Lung Cancer Action Program (ELCAP) participants in 1999 led to the International ELCAP (I-ELCAP) collaboration, which enrolled 31 567 participants in annual low-dose CT screening between 1992 and 2005.
In 2006, I-ELCAP investigators reported the 10-year lung cancer-specific survival of 80% for 484 participants diagnosed with a first primary lung cancer through annual screening, with a high frequency of clinical stage I lung cancer (85%).
Purpose
To update the cure rate by determining the 20-year lung cancer-specific survival of participants diagnosed with first primary lung cancer through annual low-dose CT screening in the expanded I-ELCAP cohort.
Materials and Methods
For participants enrolled in the HIPAA-compliant prospective I-ELCAP cohort between 1992 and 2022 and observed until December 30, 2022, Kaplan-Meier survival analysis was used to determine the 10- and 20-year lung cancer-specific survival of participants diagnosed with first primary lung cancer through annual low-dose CT screening.
Eligible participants were aged at least 40 years and had current or former cigarette use or had never smoked but had been exposed to secondhand tobacco smoke.
Results
Among 89 404 I-ELCAP participants, 1257 (1.4%) were diagnosed with a first primary lung cancer (684 male, 573 female; median age, 66 years; IQR, 61-72), with a median smoking history of 43.0 pack-years (IQR, 29.0-60.0). Median follow-up duration was 105 months (IQR, 41-182).
The frequency of clinical stage I at pretreatment CT was 81% (1017 of 1257). The 10-year lung cancer-specific survival of 1257 participants was 81% (95% CI: 79, 84) and the 20-year lung cancer-specific survival was 81% (95% CI: 78, 83), and it was 95% (95% CI: 91, 98) for 181 participants with pathologic T1aN0M0 lung cancer.
Conclusion
The 10-year lung cancer-specific survival of 80% reported in 2006 for I-ELCAP participants enrolled in annual low-dose CT screening and diagnosed with a first primary lung cancer has persisted, as shown by the updated 20-year lung cancer-specific survival for the expanded I-ELCAP cohort.
CITA DEL ARTÍCULO Radiology. 2023 Nov;309(2):e231988. doi: 10.1148/radiol.231988
Nuestros autores
